Home /Biblio

Biblio

Found 401 results
Author Keyword Title [ Type(Desc)] Year
Journal Article
W. P. McGuire, Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M., “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer”, N Engl J Med, vol. 334, pp. 1-6, 1996.
F. Joly, Ray-Coquard, I., Fabbro, M., Donoghoe, M., Boman, K., Sugimoto, A., Vaughan, M., Reinthaller, A., Vergote, I. B., Ferrandina, G., Dell'Anna, T., Huober, J., and Pujade-Lauraine, E., “Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.”, Gynecol Oncol, vol. 122, no. 2, p. 232, 2011.
G. J. S. Rustin, Vergote, I. B., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., du Bois, A., Kristensen, G. B., Jakobsen, A., Sagae, S., Greven, K., Parmar, M. K. B., Friedlander, M. Leonard, Cervantes, A., Vermorken, J. B., and Intergroup, G. Cancer, “Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)”, Int J Gynecol Cancer, vol. 21, pp. 419-23, 2011.
L. Butler, Bacon, M., Carey, M. S., Zee, B., Tu, D., and Bezjak, A., “Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial.”, J Clin Oncol, vol. 22, no. 12, pp. 2461-8, 2004.
L. C, Simes, R. J., Gebski, V., Wollschlaeger, K., Plante, M., Vergote, I. B., Maenpaa, J. U., Ferrero, A., Pisano, C., Parma, G., Berton-Rigaud, D., der W, S., Bentley, J., Reinthaller, A., Schmalfeldt, B., Hirte, H., Pfisterer, J., Pujade-Lauraine, E., and Friedlander, M. Leonard, “Development and validation of a nomogram to predict survival in CALYPSO and AGO-2.5 patients with platinum sensitive recurrent ovarian cancer. ”, Int J Gynecol Cancer , vol. 21, no. 12 Suppl 3, 2011.
A. Cull, Howat, S., Greimel, E., Waldenstrom, A. C., Arraras, J., Kudelka, A., Chauvenet, L., Gould, A., Group, E. O. R. T. C. Quality of, and Group, S. Gynaecolog, “Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report”, Eur J Cancer, vol. 37, pp. 47-53, 2001.
H. C. Kitchener, Hoskins, W. J., Small, W., Thomas, G. M., Trimble, E. L., and Group, C. Cancer Con, “The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report”, Int J Gynecol Cancer, vol. 20, pp. 1092-100, 2010.
B. Gronlund, Hansen, H. H., Hogdall, C., Hogdall, E. V., and Engelholm, S. A., “Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?”, Br J Cancer, vol. 90, pp. 377-82, 2004.
J. Pfisterer, du Bois, A., Wagner, U., Quaas, J., Blohmer, J. - U., Wallwiener, D., Hilpert, F., and Group, A. Gynakologi, “Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group”, Gynecol Oncol, vol. 92, pp. 949-56, 2004.
K. Ushijima, Kamura, T., Tamura, K., Kuzuya, K., Sugiyama, T., Noda, K., and Ochiai, K., “Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.”, Int J Clin Oncol, vol. 18, no. 1, pp. 126-31, 2013.
S. C. Crawford, Vasey, P. A., Paul, J., Hay, A., Davis, J. A., and Kaye, S. B., “Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial”, J Clin Oncol, vol. 23, pp. 8802-11, 2005.
S. V. Barrett, Paul, J., Hay, A., Vasey, P. A., Kaye, S. B., Glasspool, R. M., and Group, S. Gynaecolog, “Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial”, Ann Oncol, vol. 19, pp. 898-902, 2008.
S. Kumagai, Sugiyama, T., Shoji, T., Michimae, H., Katsumata, N., Aoki, D., Terauchi, F., Jobo, T., Ochiai, K., and Yasuda, M., “Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.”, Int J Gynecol Cancer, vol. 21, no. 9, pp. 1585-91, 2011.
P. M. Flynn, Paul, J., Cruickshank, D. J., and Group, S. Gynaecolog, “Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?”, Gynecol Oncol, vol. 86, pp. 354-7, 2002.
N. Katsumata, Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., Ochiai, K., Noda, K., and Group, J. Gynecologi, “Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial”, Lancet, vol. 374, pp. 1331-8, 2009.
F. H. van Wijk, Aapro, M. S., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A. M., de Oliveira, C. F., Tumolo, S., V. di Palumbo, S., Piccart, M. J., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M. A., Presti, M., Scarabelli, C., Splinter, T. A., Ploch, E., Beex, L. V., Huinink, W. W. ten Bok, Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E., Teodorovic, I., Coens, C., Vergote, I. B., Vermorken, J. B., Research, E. Organisati, and Group, Tof Cancer, “Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group”, Ann Oncol, vol. 14, pp. 441-8, 2003.
F. H. van Wijk, Aapro, M. S., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A. M., de Oliveira, C. F., Tumolo, S., V. di Palumbo, S., Piccart, M. J., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M. A., Presti, M., Scarabelli, C., Splinter, T. A. W., Ploch, E., Beex, L. V., Huinink, W. W. ten Bok, Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E. G. M., Teodorovic, I., Coens, C., Vergote, I. B., and Vermorken, J. B., “Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.”, Ann Oncol, vol. 14, no. 3, pp. 441-8, 2003.
D. G. Mitchell, Snyder, B., Coakley, F., Reinhold, C., Thomas, G., Amendola, M., Schwartz, L. H., Woodward, P., Pannu, H., and Hricak, H., “Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study”, J Clin Oncol, vol. 24, pp. 5687-94, 2006.
F. Heitz, Harter, P., Åvall-Lundqvist, E., Reuss, A., Pautier, P., Cormio, G., Colombo, N., Reinthaller, A., Vergote, I., Poveda, A., Ottevanger, P. B., Hanker, L. C., Leminen, A., Alexandre, J., Canzler, U., Sehouli, J., Herrstedt, J., Fiane, B., Merger, M., and A Bois, du, “Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.”, Gynecol Oncol, vol. 152, no. 2, pp. 235-242, 2019.
M. E. L. van der Burg, van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., and Pecorelli, S., “The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer”, N Engl J Med, vol. 332, pp. 629-34, 1995.
I. Ray-Coquard, Harter, P., Lorusso, D., Dalban, C., Vergote, I., Fujiwara, K., Gladieff, L., Lück, H. - J., Floquet, A., Chevalier-Place, A., Schnelzer, A., Pignata, S., Selle, F., Sehouli, J., Brocard, F., Mangili, G., Pautier, P., De Giorgi, U., Provansal, M., and Heudel, P. - E., “Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors”, JAMA Oncology, vol. 6, no. 12, p. 1923, 2020.
P. Zola, Ciccone, G., Piovano, E., Fuso, L., Di Cuonzo, D., Castiglione, A., Pagano, E., Peirano, E., Landoni, F., Sartori, E., Narducci, F., Bertetto, O., and Ferrero, A., “Effectiveness of Intensive Versus Minimalist Follow-Up Regimen on Survival in Patients With Endometrial Cancer (TOTEM Study): A Randomized, Pragmatic, Parallel Group, Multicenter Trial.”, J Clin Oncol, vol. 40, no. 33, pp. 3817-3827, 2022.
K. Kudoh, Takano, M., Kouta, H., Kikuchi, R., Kita, T., Miyamoto, M., Watanabe, A., Kato, M., Goto, T., and Kikuchi, Y., “Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers”, Gynecol Oncol, vol. 122, pp. 233-7, 2011.
G. Emons, Gorchev, G., Sehouli, J., Wimberger, P., Stähle, A., Hanker, L., Hilpert, F., Sindermann, H., Grundker, C., and Harter, P., “Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the AGO-study group (AGO G”, Gynecol Oncol, vol. 133, pp. 427-32, 2014.
C. Falandry, Rousseau, F., Mouret-Reynier, M. - A., Tinquaut, F., Lorusso, D., Herrstedt, J., Savoye, A. - M., Stefani, L., Bourbouloux, E., Sverdlin, R., D’Hondt, V., Lortholary, A., Brachet, P. - E., Zannetti, A., Malaurie, E., Venat-Bouvet, L., Trédan, O., Mourey, L., Pujade-Lauraine, E., and Freyer, G., “Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer”, JAMA Oncology, vol. 7, no. 6, p. 853, 2021.

Pages